Vaccibody.com | VACCIBODY AS TO HOST CAPITAL MARKETS DAY IN OSLO ON 3rd APRIL 2018.
1295
post-template-default,single,single-post,postid-1295,single-format-standard,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-16.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.5.2,vc_responsive

VACCIBODY AS TO HOST CAPITAL MARKETS DAY IN OSLO ON 3rd APRIL 2018.

Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, will host a capital markets day and invites analysts, brokers, investors and press to presentations by the members of the company’s executive management team and by Principal Investigator in the company’s upcoming cancer neoantigen clinical trial, Prof. Dr. med. Jürgen Krauss, Head of Section Immunotherapy, National Center for Tumor Diseases, Heidelberg.

Venue: Forskningsparken, Gaustadalléen 21, 0349 Oslo

Date: Tuesday, 3rd April 2018

Agenda:

11.00 Welcome (Tom Pike, Chairman of the Board of Directors)

11.05 Company presentation and update (Martin Bonde, CEO; Agnete B Fredriksen, President & CSO)

11.45 Need for better cancer therapies (Prof. Dr. med. Jürgen Krauss, NCT Heidelberg)

12.15 Tour in the labs & networking & sandwiches

13.00 End of day

Registration: e-mail to Lisa Gerner (lgerner@vaccibody.com)

Presentation: download here

 

About Vaccibody AS

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. Vaccibody is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. Vaccibody’s front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), which is now fully enrolled, evaluates the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).

For further information, please contact:

Martin Bonde CEO

+47 22958193

mbonde@vaccibody.com